Association Between Obesity, High-Sensitivity C-Reactive Protein ≥2 mg/L, and Subclinical Atherosclerosis | Zendy

Michael J. Blaha | Zendy; Juan J. Rivera | Zendy; Matthew J. Budoff | Zendy; Ron Blankstein | Zendy; Arthur Agatston | Zendy; Daniel H. O’Leary | Zendy; Mary Cushman | Zendy; Susan G. Lakoski | Zendy; Michael H. Criqui | Zendy; Moysés Szklo | Zendy; Roger S. Blumenthal | Zendy; Khurram Nasir | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association Between Obesity, High-Sensitivity C-Reactive Protein ≥2 mg/L, and Subclinical Atherosclerosis

Author(s) -

Michael J. Blaha,

Juan J. Rivera,

Matthew J. Budoff,

Ron Blankstein,

Arthur Agatston,

Daniel H. O’Leary,

Mary Cushman,

Susan G. Lakoski,

Michael H. Criqui,

Moysés Szklo,

Roger S. Blumenthal,

Khurram Nasir

Publication year - 2011

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.111.223768

Subject(s) - subclinical infection , c reactive protein , obesity , medicine , sensitivity (control systems) , inflammation , electronic engineering , engineering

High-sensitivity C-reactive protein (hsCRP) levels are closely associated with abdominal obesity, metabolic syndrome, and atherosclerotic cardiovascular disease. The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has encouraged using hsCRP ≥2 mg/L to guide statin therapy; however, the association of hsCRP and atherosclerosis, independent of obesity, remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research